| 000 | 02919nam a22005535i 4500 | ||
|---|---|---|---|
| 001 | 978-3-0348-0218-5 | ||
| 003 | DE-He213 | ||
| 005 | 20140220083253.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 120104s2012 sz | s |||| 0|eng d | ||
| 020 |
_a9783034802185 _9978-3-0348-0218-5 |
||
| 024 | 7 |
_a10.1007/978-3-0348-0218-5 _2doi |
|
| 050 | 4 | _aRM1-950 | |
| 072 | 7 |
_aMMG _2bicssc |
|
| 072 | 7 |
_aMED071000 _2bisacsh |
|
| 082 | 0 | 4 |
_a615 _223 |
| 100 | 1 |
_aMolineux, Graham. _eeditor. |
|
| 245 | 1 | 0 |
_aTwenty Years of G-CSF _h[electronic resource] : _bClinical and Nonclinical Discoveries / _cedited by Graham Molineux, MaryAnn Foote, Tara Arvedson. |
| 264 | 1 |
_aBasel : _bSpringer Basel, _c2012. |
|
| 300 |
_aXXII, 471p. 54 illus., 4 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 | _aMilestones in Drug Therapy | |
| 505 | 0 | _aBasic Science -- Use of rHuG-CSF in the Oncology Setting -- Use of rHuG-CSF in Non-Oncology Setting -- Safety and Economics -- The Next 20 Years. | |
| 520 | _aGranulocyte colony-stimulating factor (G-CSF or GCSF) is a secreted glycoprotein that stimulates the proliferation and differentiation of granulocyte precursor cells, and induces mobilization of peripheral blood progenitor cells from the bone marrow. Development of recombinant human G-CSF has had a profound impact on the treatment of many diseases, including severe chronic neutropenia and cancer, and has enabled peripheral stem cell transplantation to supplant bone marrow transplantation in the autologous setting. This Milestones in Drug Therapy volume describes the experience of the last 20 years of treatment with recombinant human G-CSF, including the basic science, the use of recombinant human G-CSF in both the oncology and nononcology settings, and the safety and economics of its use. Many of the authors were the original investigators of recombinant human G-CSF and other authors are key researchers who provide their outlook for the next 20 years for use of and research with recombinant human G-CSF. | ||
| 650 | 0 | _aMedicine. | |
| 650 | 0 | _aOncology. | |
| 650 | 0 | _aImmunology. | |
| 650 | 0 | _aToxicology. | |
| 650 | 0 | _aHematology. | |
| 650 | 0 | _aCytokines. | |
| 650 | 1 | 4 | _aBiomedicine. |
| 650 | 2 | 4 | _aPharmacology/Toxicology. |
| 650 | 2 | 4 | _aCancer Research. |
| 650 | 2 | 4 | _aImmunology. |
| 650 | 2 | 4 | _aCytokines and Growth Factors. |
| 650 | 2 | 4 | _aHematology. |
| 700 | 1 |
_aFoote, MaryAnn. _eeditor. |
|
| 700 | 1 |
_aArvedson, Tara. _eeditor. |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783034802178 |
| 830 | 0 | _aMilestones in Drug Therapy | |
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-0348-0218-5 |
| 912 | _aZDB-2-SBL | ||
| 999 |
_c101716 _d101716 |
||